Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis. Although neoadjuvant therapy can improve the chances of complete exeresis, not all patients respond as expected.
Epistemonikos ID: 88affd6601b4dc9991351a6bf016dadd0f2200c1
First added on: May 13, 2024